# To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

> **NCT06553027** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Cerevance** · enrollment: 330 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** CVN424 75 mg
- **DRUG:** CVN424 150 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06553027
- **Lead sponsor:** Cerevance
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553027, "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06553027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*